Search Results

Fluidigm Corporation announced that it has entered into a support agreement with Caligan Partners LP, Fluidigm’s current largest holder of common stock, under which Caligan has agreed to vote “FOR” all Fluidigm proposals related to the proposed strategic capital infusion transaction with Casdin Capital, LLC and Viking Global Investors LP at Fluidigm’s Special Meeting of Stockholders, which has been adjourned and will reconvene on April 1, 2022.

Fluidigm Corporation announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event.

Fluidigm Corporation announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP.

Fluidigm Corporation announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event.

Fluidigm Corporation urged Fluidigm stockholders to vote “FOR” ALL proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP at the Company’s upcoming Special Meeting of Stockholders.

Fluidigm Corporation announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC and Viking Global Investors LP. Fluidigm has been renamed Standard BioTools Inc. and its common stock is expected to begin trading on Nasdaq under the symbol “LAB” as of the open of market on April 6, 2022.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the fourth quarter and full year ended December 31, 2021.

Fluidigm Corporation announced preliminary revenue for the fourth quarter and full year ended December 31, 2021, exceeding the company’s guidance for those periods.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF® XT, the fourth-generation platform based on Fluidigm’s pioneering CyTOF technology.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the third quarter ended September 30, 2021.